A Liquid Formulation of a Long-acting Erythropoietin Conjugate
- 29 February 2020
- journal article
- research article
- Published by Springer Nature in Biotechnology and Bioprocess Engineering
- Vol. 25 (1) , 117-125
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Genotoxicity studies on HM10760A, recombinant human erythropoietin conjugated to globin fragmentDrug and Chemical Toxicology, 2010
- Targeted Delivery of Protein Drugs by NanocarriersMaterials, 2010
- Kinetic characterization and comparison of various protein crosslinking reagents for matrix modificationJournal of Materials Science: Materials in Medicine, 2010
- Recombinant Albumin and Transthyretin Transport Proteins from Two Gull Species and Human: Chlorinated and Brominated Contaminant Binding and Thyroid HormonesEnvironmental Science & Technology, 2009
- Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: An open-label, randomized-sequence, three-treatment, three-way crossover studyClinical Therapeutics, 2009
- Peptide and protein PEGylationBiomaterials, 2001
- Recombinant Human Albumin as a Stabilizer for Biological Materials and for the Preparation of International Reference ReagentsBiologicals, 1998
- Blockage of the urokinase receptor on the cell surface: Construction and characterization of a hybrid protein consisting of the N‐terminal fragment of human urokinase and human albuminFEBS Letters, 1994
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- The use of a water-soluble carbodiimide to cross-link cytochrome c to plastocyaninBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1983